MedTrace Logo

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea

NCT00689351 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2011-06-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Korea.

Conditions

  • Pneumococcal Vaccine

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.

BIOLOGICAL

7-valent pneumococcal conjugate vaccine

7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
98 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689351 on ClinicalTrials.gov